Information For Authors | Tromboz, Gemostaz I Reologiya

Disclaimer

The journal "Tromboz, Gemostaz I Reologiya", Publisher "Gemostaz i Reologiya", and Editors cannot be held responsible for the views and opinions expressed by individual authors of articles published herein. This also applies to any supplemental materials residing on this website that are linked to these articles. The publication of advertisements does not constitute any endorsement of products by the The journal "Tromboz, Gemostaz I Reologiya", Publisher "Gemostaz i Reologiya", or Editors.

Types of Articles

The journal «Tromboz, Gemostaz I Reologiya» publishes articles on different aspects of pathology in hhemostasis, thromboses, thrombophilias, thromboembolism, bleedings, hemorrhagic complications and disorders, disturbances in blood rheology and microcirculation, fundamental issues of hemostasis system and hemorheology, as well as on related medical specialities.

Accepted types of articles:
1. Original papers. Results of researches. Accepted papers present the data of researches in clinical hemostasiology and hemorheology. Results of clinical studies are not accepted.
2. Technology reviews. Reviews describing novel methods and technologies and their application in clinical and fundamental hemostasiology and hemorheology.
3. Reviews. Reviews of current advances in clinical and fundamental hemostasiology and hemorheology.
4. Clinical cases. Descriptions of rare clinical cases or cases that represent a diagnostic challenge providing analysis and discussion of the presented data.

General information

2.1. Publication Ethics. The journal «Tromboz, Gemostaz I Reologiya» adheres to the Publication Ethics and ethical standards for publication in the journal, which are listed Here (link). Before sending the manuscript all authors are encouraged to review the publication ethics section.
2.2 Review. All articles submitted to the editorial office, pass the review procedure. The reviewing procedure is described Here (link)
The Editorial Board reserves the right to shorten and edit articles.
2.3. Publication fees. Publication of articles in the journal is free of charge. Author’s copy of the journal is not provided.
2.4. Plagiarism. Only materials that have never been published or have been submitted for publication elsewhere can be accepted for printing. Copying text without authorization is forbidden. Submitted manuscripts are checked for plagiarism. The amount of text similarity should not more than 20%.
2.5. Copyright. Authors sign an Agreement on the transfer of the exclusive license for the text to «Gemostaz I Reologiya» LLC, which allows to publish articles in the journal. The license is valid in all countries for the duration of the copyright.
2.6 Conflicts of Interest. Authors are required to submit information about potential conflicts of interest, including financial, personal and other relationships with other persons or organizations that could potentially lead to the distortion of data presented in the manuscript, for 3 years prior to the date of submission. These conflicts of interest, as well as a statement of their absence should be provided in the relevant section of the manuscript and the conflicts of interest form.
2.7. Information on funding sources. If reliable, indicate funding sources. In the absence of funding sources, the authors need to state this in the relevant section of the manuscript and the conflicts of interest form.

Authorship requirements

Authorship requirements were composed in accordance with the recommendations for medical journal editors of the International Committee (ICMJE). All those qualifying for authorship should meet all four of the following criteria:
1. Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work;
2. Drafting the work or revising it critically for important intellectual content;
3. Final approval of the version to be published;
4. Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.”

The authors should be identified before submitting the manuscript. All those who participated in the preparation of work (technicians, etc.), but do not meet authorship requirements, may be listed in the “acknowledgements”. One author responsible for contact with the editorial board should be indicated at the time of submission. This author should be available for contact during the peer-review procedure, as well as after the publication of the article. The author responsible for contact with the editorial board should be able to provide answers, comments and additional information if required.

Submitting a manuscript

A set of documents to be sent to the Editor of the Journal

The electronic version of the manuscript.
The author’s agreement (ссылка copyright agreement).
A cover letter (cover letter template).
The conflicts of interest form

The manuscript can be submitted through:

The electronic submission form at the journal website (will be available soon)
E-mail, accompanied with scans of required forms.

Guidelines for authors

5.1 General
The article should be printed using a 12-point font size, double-spaced on a A4 paper dimensions with margins of 2.5 cm on all sides of the text.
All units must be specified in the SI system.
All drugs should be given in the form of International Nonproprietary Names (INN).
Abbreviations which are not widely accepted, must be deciphered at their first occurrence in text.
In the original article provides information on the approval of the research ethics committee.

5.2. Title page
The title page should include:
1) The title of the article – short and informative;
2) the names of authors followed by their highest academic degrees (MD, PhD) and their position and institutional affiliations;
3) full name of the institution(s) where the work was performed;
4) Complete mailing address, zip code, telephone and fax numbers, e-mail address of the сorresponding author;
5) abbreviated title to be placed on top of the journal pages

5.3. Abstract and keywords
The abstract is the most important section of the article. The Abstract should reflect the content of the article and briefly describe the main objectives of the study, explain how the study was conducted without methodological details, summarize the most important results including key quantitative data and indicating their statistical significance and their importance, what conclusions can be drawn.

References and abbreviations, which are not widely accepted should be avoided. If necessary this type of abbreviations should be decrypted.

For original articles a structured format of abstract is required. The abstract should include following sections: introduction, objective, materials and methods, results, conclusion. The abstract should be 200-250 words.

3-6 keywords should be provided. The keywords should reflect the main content of the article and facilitate the search of articles when using of information search systems.

The Abstract and key words should be presented in Russian and English. The English version of the abstract should not be a direct translation of the Russian version. As the Russian version, the English version should give a brief, structured, lucid description of the study. For the English keywords it is recommended to use a dictionary of medical terms Medline (MeSH).

Abstract examples

Russian:

Полиморфизм гена IL2-330Т>G и экспрессия интерлейкина-2 у больных с венозными тромбоэмболическими осложнениями политравмы.

Мироманов А.М., Доржеев В.В., Мироманова Н.А., Витковский Ю.А.

ФГБОУ ВО «Читинская государственная медицинская академия» Министерства здравоохранения, Чита, Россия

Аннотация

Введение. Политравма отличается особой тяжестью клинических проявлений, сопровождается значительным нарушением жизненно важных функций организма, трудностью диагностики и лечения, частым развитием разнообразных осложнений, длительным периодом пребывания в стационаре и высокой инвалидизацией.

Цель. Целью исследования было изучить влияние полиморфизма гена IL2-330T>G на экспрессию интерлейкина-2 (IL-2) у пациентов с венозными тромбоэмболическими осложнениями (ВТЭО) политравмы в Забайкальском крае.

Материалы и методы. В исследование включено 114 пациентов (71,9% мужчин и 28,1% женщин) в возрасте от 20 до 40 лет с политравмой. Критерий включения в исследование: политравма с индексом по шкале ISS более 9. Первая группа – 73 пациента с неосложнённым течением политравмы, вторая группа – 41 пациент с ВТЭО политравмы. Контрольную группу составили 100 практически здоровых мужчин и женщин в возрасте от 20 до 40 лет. Материалом для молекулярно-генетического анализа служили образцы ДНК, выделенные из периферической крови. Для исследования выбрана точковая мутация IL-2 в позиции 330 (Т>G).

Результаты. У пациентов с ВТЭО политравмы регистрировали более частое носительство генотипа -330T/T гена IL2; наличие этого генотипа сопровождалось увеличением продукции IL-2.

Заключение. У пациентов с венозными тромбоэмболическими осложнениями политравмы регистрируется более высокое носительство аллели -330Т- и генотипа -330Т/Т гена IL2. Наличие в геноме генотипа -330Т/Т гена IL2 способствует более высокой экспрессии IL-2.

English:

Introduction. Polytrauma is characterized by a special severity of clinical manifestations, accompanied by significant violations of the vital functions of the body, difficulty of diagnosis and treatment, the common development of various complications, long hospital stay and high morbidity.

Aim. The aim of the study was to examine the impact of gene polymorphism in the IL2-330T>G on the expression of interleukin-2 (IL-2) in patients with venous thromboembolic complications (VTEC) polytrauma in Zabaykalsky Krai.

Materials and methods. The study included 114 patients (71,9% of men and 28.1% women) aged 20 to 40 years with multiple injuries. The criterion for inclusion in the study: polytrauma index according to ISS more than 9. The first group of 73 patients with uncomplicated course of polytrauma, the second group – 41 patient with polytrauma VTEC. The control group consisted of 100 healthy men and women aged 20 to 40 years. Material for molecular genetic analysis were DNA samples isolated from peripheral blood. Selected for the study of point mutation of IL-2 at position 330 (T>G).

Results. Patients with VTEC polytrauma was recorded more frequent carriers of the genotype -330T/T IL2 gene; the presence of this genotype was accompanied by increased production of IL-2.

Conclusion. In patients with venous thromboembolic complications of polytrauma recorded higher accumulation of allele -330Т - and genotype -330Т/T gene IL2. The presence in the genome of genotype -330Т/T IL2 gene promotes higher expression of IL-2.

5.4. The article
Original papers
The average volume of articles should be2000-4000 words. The number of references should not exceed 25. The number of images – not more than 8.

Original papers should include following sections:

1) title page;
2) Abstract;
3) keywords and abbreviated title;
4) Introduction;
5) Materials and methods;
6) Results;
7) Discussion;
8) References;
9) Information on conflict of interest and funding source;
10) Aknowledgements;
11) information on compliance with ethical standards *
* Approval of the research ethics committee.

The abstract of an original paper must repeat the structure of the article and should include following sections: introduction, objective, materials and methods, results, discussion, conclusion.

Introduction. The objectives and importance of the study should be presented. Current information on the research topic should be summarized with reference to the most relevant and recent publications as possible.
Materials and methods. Quantitative and qualitative characteristics of patients, characteristics of the experimental materials should be listed. All the research methods, including statistical methods of data processing should be described. Description of the methods should enable to reproduce them. The manufacturer and the country of the equipment and new drugs used in the study should be cited.
Results. Results should be presented in a logical order in the text, tables, and figures. The text should not repeat all the data from the tables and figures, it is necessary to mention only the most important ones. The figures should not duplicate data given in the tables. The place in the text where a picture should be placed may be marked with a square with its number.
Discussion. This section should summarize obtained results and highlight new and important aspects of the study in comparison with the data obtained by other authors. Do not repeat the information that was already provided in the “Introduction” section or duplicate the details of the “Results” section. If appropriate some practical recommendations may be suggested. A brief conclusion may be present.

Reviews, technology reviews
The average volume of the article should be 2000-4000 characters, the number of references can be up to 40. The presence of illustrative material is welcome. The article can be divided in subsections.

Structure of the article:
The manuscript should include following sections:

1) title page;
2) Abstract;
3) keywords and abbreviated title
4) Review text (possible division into subsections);
5) Information about the conflict of interest and funding sources;
6) Aknowledgements;
7) References.

Clinical cases

The average volume of the article should be 1500-3000 characters. The number of references in the bibliography – not more than 10. Illustrative material presence is welcome.

Structure of the article:
The manuscript should include following sections:

1) title page;
2) Abstract;
3) keywords and abbreviated title;
4) Introduction
5) Description of the cases;
6) Information about the conflict of interest and funding sources;
7) Aknowledgements;
8) References.

Introduction – The importance of the case reports, summarizes the state of the question, with reference to the most relevant and recent publications as possible.

Description of cases – Detailed description of medical history, clinical presentation, laboratory data and instrumental methods, applied therapeutic approaches should be described. 1-3 patients may be presented.

Discussion. The most important aspects of clinical case descriptions should be highlighted. Comparison with other similar clinical cases reported should be performed. Do not repeat the information that was already provided in the “Introduction” section. If appropriate some practical recommendations may be suggested. A brief conclusion may be present.

5.5. Pictures
Pictures (images, diagrams, photographs) are submitted in two copies. Photos must be presented with a minimum resolution of 300 dpi (1:1). Three-dimensional images are not accepted.
Each Picture should be presented in a separate file of an acceptable format.
For each picture its name and legend, explaining parts of the figure, the symbols, arrows and other items that may be unclear should be presented. Figure titles and legends should be printed on a separate page, with two line spacing and numbered corresponding to the numbers of Pictures. In microphotographs coloring (if necessary) and the magnification should be indicated.
Acceptable formats: JPG, TIFF, PNG
Unacceptable formats: GIF, BMP, PICT, WPG.
Reprinted images may be accepted only if a special permission is obtained.

5.6. Tables
Tables should be included as a part of the manuscript document file and numbered in the order of their mention in the text. The number and name of the table should be given above the table. Each column in the table must have a short title (if necessary abbreviations may be used). All explanations, including decifering of abbreviations should be placed in the legend. It is desirable to specify the statistical methods and significances of the data provided in the tables.

5.7. Mathematical formulas
Mathematical formulas are presented in the text. The variables are presented in italics. If the division sign is present in the formula it is placed as a sloping rather than a horizontal line.

5.8. Conflict of interest
In case of absence of conflicts of interest it is stated that “there is no conflict of interest.” In other cases, a description of existing and potential conflicts of interest is provided.

5.9. Funding sources
A lists of funding sources of the research is presented. If there are no funding sources it is claimed.

5.10. Aknowledgements
Aknowledgements is the section in which authors may express appreciation to others who have contributed to the study but did not meet authorship criteria, and organizations that participated in the study. Maximum length 100 words.

5.11. References
References should be printed on a separate sheet or sheets with two line spacing, each source with a new line under the serial number. All studies should be listed in the order they appear in the text. When mentioned in the text authors’ names should be preceded by the initials (names of foreign authors in this case are given in the original transcription). Bibliographic references should be cited in numerical order according to their position in the text in square brackets.

It is not recommended to include thesis in the reference list because it may be a challenge to access the full text.

The information in the references should be placed in following order: a) Author (s); b) Title; c) journal(book), year of publication, volume, №, pages; g) DOI and PMID numbers, if available.

When the group of authors is up to four all of the authors are mentioned (with the initials after surnames). If there are more authors the names of the first three are provided with “et al.” after. If authors are presented by the editors of the book (“Ed.”) should be put in after the name of the last of them.

In book references the city, where it was published, followed by the publisher name, and the year of publication should be presented after the title. In references to book chapters the authors and the title of the chapter is first mentioned, after that put “In:’ and the name (s) of the author (s) or editor (s), the title and imprint of the book.

In journal article references the abbreviated journal name, year of publication, volume and issue, pages are listed after the title of the article.

For each article, an additional References list hould be created, in which all russian references will be given in the Roman alphabet. English references remain unchanged.

Samples of references

Abstracts of conferences:

Гришин Е.В., Королькова Ю.В., Tseng G.N. Биологическая активность С-концевого фрагмента аргинин вазопрессина. Молекулярный механизм блокирования токсином скорпиона калиевого канала ERG-типа. Всероссийский симпозиум по химии и биологии пептидов: тезисы докл. М. 2003: 30.

Grishin E.V., Korolkova Yu.V., Tseng G.N. Biological activity of the C-terminal fragment of arginine vasopressin. Molecular mechanism of blocking the toxin scorpion potassium channel ERG-type [Biologicheskaya aktivnost' S-koncevogo fragmenta arginin vazopressina. Molekulyarnyj mekhanizm blokirovaniya toksinom skorpiona kalievogo kanala ERG-tipa]. Vserossijskij simpozium po himii i biologii peptidov: tezisy dokl. Moscow. 2003: 30 (in Russian).

Journal articles:

Pounder R.E., Ng D. The prevalence of Helicobacter pylori infection in different countries. Aliment Pharmacol Ther. 1995; 9 (Suppl 2): 33-9.

Бардахчьян Э.А., Ломов С.Ю., Харланова Н.Г., Камнева Н.В. Роль Helicobacter pylori при развитии экстрагастродуоденальных заболеваний. Экспериментальная и клиническая гастроэнтерология. 2005; 3: 20-7.

Bardakhchyan E.A., Lomov S.Yu., Kharlanov N.G., Kamneva N.V. The role of Helicobacter pylori in the development of extrastastroduodenal diseases [Helicobacter pylori pri razvitii ehkstragastroduodenal'nyh zabolevanij]. Eksperimental'naya i klinicheskaya gastroehnterologiya. 2005; 3: 20-7 (in Russian).

Monographs, books and chapters in books:

Гуманенко Е.К., Супрун Т.Ю., Бояринцев В.В. Комплексная оценка тяжести травм. Методические рекомендации: «Механические травмы и огнестрельные повреждения». СПб.: Военно-медицинская академия. 1995: 43 с.

Gumanenko E.K., Suprun T.Yu., Boyarintsev V.V. Comprehensive assessment of the severity of injuries [Kompleksnaya ocenka tyazhesti travm. Metodicheskie rekomendacii: «Mekhanicheskie travmy i ognestrel'nye povrezhdeniya»]. Saint-Petersburg: Voenno-medicinskaya akademiya. 1995: 43 s (in Russian).

Patents:

Лебедев В.П., Малыгин А.В. Sposob transkranial'noi elektrostimuliatsii endorfinnykh mekhanizmov Мозга я ustroistvo dlia эго osushchestvleniia [способ TES и соответствующее устройство для мозга эндорфинов стимуляции системы]. Патент РФ, нет. 2159639, 1999. (в рус.).

Лебедев В.П., Малыгин А.В. «Способ транскраниальной электростимуляции эндорфинных механизмов мозга и устройство для его осуществления» Патент РФ №2159639 на изобретение, 1999.

Dissertations:

Гуманенко Е.К. Сочетанные травмы с позиции объективной оценки тяжести травм. Автореф. дис. докт. мед. наук. Л. 1992: 28 с.

Gumanenko E.K. Combined trauma from the position of an objective assessment of the severity of injuries [Sochetannye travmy s pozicii ob"ektivnoj ocenki tyazhesti travm]. Avtoref. dis. dokt. med. nauk. Leningrad. 1992: 28 s (in Russian).

Online publications and databases

Бережняк И.В., Григоричева Л.Г., Момот А.П., Меркулов И.В. Эффективность и безопасность современных схем тромбопрофилактики при эндопротезировании тазобедренного сустава. Современные проблемы науки и образования [Электронный ресурс]. 2016; 3. Доступно на: http://www.science-education.ru/ru/article/view?id =24708 (дата обращения: 6.02.2017).

Berezhnyak I.V., Grigoricheva L.G., Momot A.P., Merkulov I.V. Effectiveness and safety of modern thromboprophylaxis regimens for hip arthroplasty [Effektivnost' i bezopasnost' sovremennyh skhem tromboprofilaktiki pri ehndoprotezirovanii tazobedrennogo sustava]. Sovremennye problemy nauki i obrazovaniya [Elektronnyj resurs]. 2016; 3. Dostupno na: www.science-education.ru/ru/article/view?id =24708 (data obrashcheniya: 6.02.2017)